45 related articles for article (PubMed ID: 24342730)
1. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.
Volovat C; Gladkov OA; Bondarenko IM; Barash S; Buchner A; Bias P; Adar L; Avisar N
Clin Breast Cancer; 2014 Apr; 14(2):101-8. PubMed ID: 24485296
[TBL] [Abstract][Full Text] [Related]
2. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
3. NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
Kirshner JJ; McDonald MC; Kruter F; Guinigundo AS; Vanni L; Maxwell CL; Reiner M; Upchurch TE; Garcia J; Morrow PK
Support Care Cancer; 2018 Apr; 26(4):1323-1334. PubMed ID: 29147854
[TBL] [Abstract][Full Text] [Related]
4. Update on adjuvant chemotherapy for early breast cancer.
Rampurwala MM; Rocque GB; Burkard ME
Breast Cancer (Auckl); 2014; 8():125-33. PubMed ID: 25336961
[TBL] [Abstract][Full Text] [Related]
5. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.
Burkard ME; Wisinski KB; Njiaju UO; Donohue S; Hegeman R; Stella A; Mansky P; Shah V; Goggins T; Qamar R; Dietrich L; Kim K; Traynor AM; Tevaarwerk AJ
Clin Breast Cancer; 2014 Jun; 14(3):205-11. PubMed ID: 24342730
[TBL] [Abstract][Full Text] [Related]
8. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
[TBL] [Abstract][Full Text] [Related]
9. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
Ngamphaiboon N; O'Connor TL; Advani PP; Levine EG; Kossoff EB
Med Oncol; 2012 Sep; 29(3):1495-501. PubMed ID: 21818673
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
[TBL] [Abstract][Full Text] [Related]
11. [Feasibility of adjuvant docetaxel plus cyclophosphamide therapy for breast cancer].
Naito K; Oura S; Yoshimasu T; Nakamura R; Hirai Y; Kiyoi M; Miyasaka M; Okamura Y
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1913-6. PubMed ID: 20948255
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
13. The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.
Younis T; Rayson D; Skedgel C
Curr Oncol; 2011 Dec; 18(6):e288-96. PubMed ID: 22184496
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.
Berry DA; Ueno NT; Johnson MM; Lei X; Caputo J; Rodenhuis S; Peters WP; Leonard RC; Barlow WE; Tallman MS; Bergh J; Nitz UA; Gianni AM; Basser RL; Zander AR; Coombes RC; Roché H; Tokuda Y; de Vries EG; Hortobagyi GN; Crown JP; Pedrazzoli P; Bregni M; Demirer T
J Clin Oncol; 2011 Aug; 29(24):3214-23. PubMed ID: 21768471
[TBL] [Abstract][Full Text] [Related]
15. Correlation between docetaxel-induced skin toxicity and the use of steroids and H₂ blockers: a multi-institution survey.
Kawaguchi K; Ishiguro H; Morita S; Nakamura S; Ohno S; Masuda N; Iwata H; Aogi K; Kuroi K; Toi M;
Breast Cancer Res Treat; 2011 Nov; 130(2):627-34. PubMed ID: 21698408
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
